Irina A. Merkulova

Irina A. Merkulova

Auto-generated profile, based on publicly available information

Irina A. Merkulova

Chazov National Medical Research Center of Cardiology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2021 in Journal of Arrhythmology
Verified
Journal Article
Open access
PDF file
DPD. V. Pevzner
D. V. Pevzner
EME. V. Merkulov
E. V. Merkulov
GAG. K. Arutyunyan
G. K. Arutyunyan
AKA. L. Komarov
A. L. Komarov
OSO. O. Shakhmatova
O. O. Shakhmatova
ICI. E. Chazova
I. E. Chazova
The aimof our study was to evaluate implantation efficacy and safety across various occluder types and to identify factors determining device selection.Methods. This single-site prospective observational study included patients above the age of 40 years with non-valvular atrial fibrillation (AF) and high thromboembolic risk, undergoing endovascular isolation of the left atrium appendage (LAA) with Watchman or Amplatzer Cardiac Plug/Amulet devices. Occluders were implanted to patients without either had contraindications to anticoagulant therapy (ACT) or refused ACT. We evaluated technical aspects of device implantation, short- and long-term outcomes of the intervention over 3 years of follow-up.Results. 90 patients were enrolled in the study (62 into the Watchman arm and 28 into the Amplatzer arm). Interventions were technically successful in 89 cases. In 1 patient (1/90, 1.1%) technical success was not achieved due to device migration (Amplatzer Amulet). The incidence of early (occurring within˂ 24 hours) implantation complications was 0% in the Watchman arm, and 3.6% in the Amplatzer arm (1/28) (р=0.135) (device migration). The cumulative incidence of all in-hospital complications was 11.3% and 14.3%, respectively (р=0.734). No significant differences between arms were found in the incidence of device thrombosis within 90 days post-implantation (3.3% in the Watchman’s arm and 8.3% in the Amplatzer arm, р=0.316). During the observation period, there were no significant differences in comparison groups in the incidence of net clinical efficacy endpoint events (р=0.58). The bleeding rate was 17.7% and 14.3%, respectively, р=0.769. No factors influencing the choice of the device could be identified reliably; however, there was a trend towards Watchman preference for appendage anatomic variants such as broccoli and cactus. Amplatzer was preferred in patients with contraindications to ACT.Conclusion.Implantation of Watchman and Amplatzer Amulet occluders is equally effective and safe in preventing thromboembolism in patients with AF not receiving ACT for various reasons. The individual choice of a device may be influenced by appendage anatomy and indications to occluder implantation.

12 April 2023 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
DPD. V. Pevzner
D. V. Pevzner
NKN. S. Kostritsa
N. S. Kostritsa
LGL. M. Galaeva
L. M. Galaeva
IMI. A. Merkulova
I. A. Merkulova
ODO. B. Dorogun
O. B. Dorogun
AKA. L. Komarov
A. L. Komarov
Aim. To identify risk factors for low adherence and develop a scale for its pre­diction. To evaluate the association of the predictive score with actual low adherence according to the 8-item Morisky Medication Adherence Scale, self-drug withdrawal, and adverse outcomes in patients with atrial fibrillation (AF).Material and methods. The study included patients with AF and a high risk of thromboembolic events according to the CHA2DS2-VASc scale, who were hospitalized from January 2011 to December 2017. Potential risk factors for non-adherence, selected from the literature, were tested in a multivariate regression analysis followed by the development of an adherence prediction scale. The asso­ciation of predicted low adherence with actual adherence was assessed.Results. The study included 199 patients. The analysis identified following predictors of low adherence: low income, history of bleeding, prior stroke, 4 positive responses to the adherence questionnaire, warfarin. Based on these predictors, a scale for predicting adherence was developed, while a threshold value of 3 points was identified (sensitivity, 90,2%, specificity, 98,4%). A significant association of low predicted adherence on the developed scale with actual adherence and adverse outcomes was demonstrated.Conclusion. We have developed a scale for predicting adherence to anticoagulant therapy, and also determined its threshold value. In case of a high risk of low adherence, clinicians should try to increase adherence in order to prevent comp­lications.

10 October 2024 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ZSZh. A. Shakhramanova
Zh. A. Shakhramanova
ONO Yu. Narusov
O Yu. Narusov
VAV. A. Amanatova
V. A. Amanatova
YOYu. F. Osmolovskaya
Yu. F. Osmolovskaya
KGK. G. Ganaev
K. G. Ganaev
ЮОЮ. Ф. Осмоловская
Ю. Ф. Осмоловская
Aim. To study mortality, postoperative complications, clinical course, and quality of life of patients with heart failure (HF) within 6 months after left ventricular assist device (LVAD) implantation.Material and methods. The study included 53 patients who met the criteria for LVAD implantation. Twenty three patients underwent surgery (group 1), while 30 patients refused implantation (group 2). The follow-up period was 6 months. The death number and causes, hospitalization and HF decompensation rates, the changes of N-terminal pro-brain natriuretic peptide levels, the functional class of HF, the incidence of postoperative complications were assessed. Exercise tolerance (ET) was determined using a 6-minute walk test, while quality of life — using the EQ-5D questionnaire.Results. Patient mortality in the LVAD group was 26%, while in group 2 — 23,3%. In the main group, 1 patient died due to cardiovascular cause; 2 — gastrointestinal bleeding; 1 — infectious complications (sepsis); 1 — cerebrovascular accident; 1 — acute non-occlusive mesenteric ischemia. In the control group, all death cases were due to cardiovascular pathology. Among the complications after implantation, the most common were pleurisy, delirium, ventricular tachycardia, right ventricular failure, gastrointestinal bleeding, LVAD-associated infection. In group 1, there was a significantly lower number of rehospitalizations compared to group 2, including those due to HF decompensation (p=0,034, p<0,001, respectively). In the main group, there was an improvement in the quality of life (p<0,001), HF class (p<0,001), and ET (p=0,006), which led to a reliable difference between the groups after 6 months.Conclusion. LVAD implantation is accompanied by a decrease in the number of rehospitalizations and HF decompensation, as well as improvement of ET, HF class and quality of life of patients, but not a decrease in mortality. To reduce the incidence of postoperative complications and improve the prognosis, a more careful selection of patients for intervention, assessment of their cognitive status and compliance is necessary.

6 August 2025 in Kardiologiia
Verified
Journal Article
Open access
PDF file
IMI. A. Merkulova
I. A. Merkulova
NGN. S. Germanov
N. S. Germanov
ZBZ. B. Bashankaeva
Z. B. Bashankaeva
IYI. S. Yavelov
I. S. Yavelov
DPD. V. Pevzner
D. V. Pevzner
SBSergey Boytsov
Sergey Boytsov
Pulmonary embolism (PE) is a complex emergency condition, the diagnosis and treatment of which still have many unresolved issues and "gray areas". Current clinical guidelines for the management of patients with PE are partly outdated and do not take into account a number of modern data. In this review, the authors identified unresolved issues and provided the latest data on the assessment of pre-test probability, risk stratification, diagnosis and treatment of acute PE, particularly in patients with intermediate-high and high risk of death. The issues of reperfusion catheter techniques and intensive care are addressed individually. The requirement for specialized PE centers of expert level and their prospects are discussed

8 September 2022 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
DPD. V. Pevzner
D. V. Pevzner
NKN. S. Kostritca
N. S. Kostritca
AAA. K. Alieva
A. K. Alieva
IMI. A. Merkulova
I. A. Merkulova
IYI. S. Yavelov
I. S. Yavelov
ICI. E. Chazova
I. E. Chazova
Aim. To study the outcomes frequency and structure in patients with atrial fibrillation (AF) depending on the cardioembolic events preventing method: left atrial appendage (LAA) isolation, direct oral anticoagulants (DOACs) or warfarin.Material and methods. A prospective observational study included patients with AF and high risk of cardioembolic complications and without contraindications to anticoagulants. Patients who refused long-term oral anticoagulants taking underwent LAA isolation, the rest of the patients received DOACs or warfarin. The observation period was 3 years. Mortality, cardioembolic complications and major bleeding (according to GARFIELD criteria) cumulative incidence was assessed.Results. We included 245 patients: 46 patients were treated with LAA isolation, 100 with warfarin, and 99 with DOACs. Multivariate regression analysis demonstrated a statistically significant advantage of LAA occluder in terms of combined endpoint achieving frequency compared to warfarin (hazard ratio [HR] 3.10; 95% confidence interval [CI] 1.01-9.54; p=0.049), and to DOACs (HR 3.44, 95% CI 1.15-10.29; p=0.027). A similar result was obtained for all-cause mortality (HR 5.24; 95% CI 1.12-24.55; p=0.036 and HR 5.58; 95% CI 1.22-25.49; p=0.027, respectively). There were no significant differences in bleeding rates between the groups.Conclusion. This observational study demonstrates the superiority of LAA isolation as a first-line therapy over DOACs and warfarin in patients with AF and high risk of cardioembolic complications. Randomized trials are required to confirm these observations.

1 January 2022 in Russian Cardiology Bulletin
Verified
Journal Article
Closed access
DPD.V. Pevzner
D.V. Pevzner
IMI.A. Merkulova
I.A. Merkulova
AKA.L. Komarov
A.L. Komarov
GAG.K. Arutyunyan
G.K. Arutyunyan
AUA.M. Ushanova
A.M. Ushanova
ICI.E. Chazova
I.E. Chazova